Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
AssigneesEndeavor Health Clinical Operations, Multivir Inc.
InventorsPrem Seth, Sunil Chada, Dora Wiederhold, Kerstin B. Menander, Robert E. Sobol
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an adenoviral vector with a genetically modified fiber incorporating a Lyp-1 peptide motif and at least one CD122/CD132 agonist and/or an immune checkpoint inhibitor.
Claims6
A pharmaceutical composition comprising (a) Lyp-1 chimeric adenovirus particles encoded by a chimeric adenovirus E1A 01/07 mutant vector comprising a genetically modified fiber gene encoding a fiber incorporating a LyP-1 peptide within the HI loop of the fiber, wherein the vector encodes a soluble TGFβ receptor II Fc fusion protein (sTGFβRIIFc) and Adenoviral 5/Adenoviral 48 (Ad5/48) chimeric hexon, (b) at least one CD122/CD132 agonist selected from the group consisting of an IL-2/anti-IL-2 immune complex, an IL-15/anti-IL-15 immune complex, an IL-15/IL-15 Receptor α-IgG1-Fc (IL-15/IL-15Rα-IgG1-Fc) immune complex, PEGylated IL-2, PEGylated IL-15, IL-2 mutein and/or IL-15 mutein, and (c) at least one immune checkpoint inhibitor.
Dependencies are inferred from the claim text.